126 related articles for article (PubMed ID: 10365674)
1. Detection of residual and recurrent thyroid cancer by radionuclide imaging.
Maxon HR
Thyroid; 1999 May; 9(5):443-6. PubMed ID: 10365674
[TBL] [Abstract][Full Text] [Related]
2. Isotope imaging for metastatic thyroid cancer.
Haugen BR; Lin EC
Endocrinol Metab Clin North Am; 2001 Jun; 30(2):469-92. PubMed ID: 11444171
[TBL] [Abstract][Full Text] [Related]
3. RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER.
Solodyannikova OI; Kmetyuk YV; Danilenko VV; Sukach GG
Probl Radiac Med Radiobiol; 2020 Dec; 25():579-591. PubMed ID: 33361863
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
[TBL] [Abstract][Full Text] [Related]
5. Influence of thyroid-stimulating hormone on 18F-fluorodeoxyglucose and 99mTc-methoxyisobutylisonitrile uptake in human poorly differentiated thyroid cancer cells in vitro.
Kim CH; Yoo IeR; Chung YA; Park YH; Kim SH; Sohn HS; Chung SK
Ann Nucl Med; 2009 Feb; 23(2):131-6. PubMed ID: 19225935
[TBL] [Abstract][Full Text] [Related]
6. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD
J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
[TBL] [Abstract][Full Text] [Related]
7. FDG positron emission tomographic, radioiodine, and MIBI imaging in a patient with poorly differentiated insular thyroid carcinoma.
Zettinig G; Leitha T; Niederle B; Kaserer K; Becherer A; Kletter K; Dudczak R
Clin Nucl Med; 2001 Jul; 26(7):599-601. PubMed ID: 11416738
[TBL] [Abstract][Full Text] [Related]
8. Non-131I-scintigraphy in the treatment and follow-up of thyroid cancer. Single-photon-emitters or FDG-PET?
Grünwald F; Briele B; Biersack HJ
Q J Nucl Med; 1999 Sep; 43(3):195-206. PubMed ID: 10568135
[TBL] [Abstract][Full Text] [Related]
9. [99m-Tc-MIBI for recurrent and metastatic differentiated thyroid carcinoma].
Elser H; Henze M; Hermann C; Eckert W; Mende U
Nuklearmedizin; 1997 Jan; 36(1):7-12. PubMed ID: 9082340
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 201Tl, 99Tcm-MIBI and 131I imaging in the follow-up of patients with well-differentiated thyroid carcinoma.
Uğur O; Kostakoğlu L; Caner B; Güler N; Gülaldi NC; Ozmen M; Uysal U; Elahi N; Erbengi G; Bejdik C
Nucl Med Commun; 1996 May; 17(5):373-7. PubMed ID: 8736512
[TBL] [Abstract][Full Text] [Related]
11. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid cancer--comparison study with 131I and 201Tl].
Nagamachi S; Jinnouchi S; Nishii R; Flores LG; Nakahara H; Futami S; Tamura S; Toshimori H; Kawai K
Kaku Igaku; 2000 Mar; 37(2):89-98. PubMed ID: 10783567
[TBL] [Abstract][Full Text] [Related]
13. [Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2)].
Dietlein M; Dressler J; Eschner W; Leisner B; Reiners C; Schicha H; ;
Nuklearmedizin; 2003 Jun; 42(3):123-5. PubMed ID: 12802477
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer.
Campennì A; Violi MA; Ruggeri RM; Sindoni A; Moleti M; Vermiglio F; Baldari S
Nucl Med Commun; 2010 Apr; 31(4):274-9. PubMed ID: 20087239
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
16. Nuclear imaging in the management of thyroid carcinoma.
Cavalieri RR
Thyroid; 1996 Oct; 6(5):485-92. PubMed ID: 8936676
[TBL] [Abstract][Full Text] [Related]
17. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
Haugen BR; Pacini F; Reiners C; Schlumberger M; Ladenson PW; Sherman SI; Cooper DS; Graham KE; Braverman LE; Skarulis MC; Davies TF; DeGroot LJ; Mazzaferri EL; Daniels GH; Ross DS; Luster M; Samuels MH; Becker DV; Maxon HR; Cavalieri RR; Spencer CA; McEllin K; Weintraub BD; Ridgway EC
J Clin Endocrinol Metab; 1999 Nov; 84(11):3877-85. PubMed ID: 10566623
[TBL] [Abstract][Full Text] [Related]
18. [Value of scintigraphic explorations by radiomarkers others than iodine radioisotope in differentiated thyroid cancer].
Sassolas G; Houzard C; Sigartau C; Borson-Chazot F
Ann Endocrinol (Paris); 1997; 58(1):55-63. PubMed ID: 9207967
[TBL] [Abstract][Full Text] [Related]
19. The use of imaging studies in the diagnosis and management of thyroid cancer and hyperparathyroidism.
James C; Starks M; MacGillivray DC; White J
Surg Oncol Clin N Am; 1999 Jan; 8(1):145-69. PubMed ID: 9824366
[TBL] [Abstract][Full Text] [Related]
20. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
